Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay—Results From the SAFIA Phase III Trial

Khalid AlSaleh; Heba Al Zahwahry; Adda Bounedjar; Mohammed Oukkal; Ahmed Saadeddine; Hassen Mahfouf; Kamel Bouzid; Assia Bensalem; Taha Filali; Hikmat Abdel-Razeq; Blaha Larbaoui; Alaa Kandil; Omalkhair Abulkhair; Meteb Al Foheidi; Hassan Errihani; Marwan Ghosn; Nashwa Abdel-Aziz; Maria Arafah; Hamouda Boussen; Farida Dabouz; Haleem Rasool; Mohun Bahadoor; Jihen Ayari; Sharif Kullab; Jean-Marc Nabholtz; Int Canc Res Grp

doi:10.1200/GO.20.00575

Back

Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay—Results From the SAFIA Phase III Trial

Journal article

Open access

Peer reviewed

Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay—Results From the SAFIA Phase III Trial

Khalid AlSaleh, Heba Al Zahwahry, Adda Bounedjar, Mohammed Oukkal, Ahmed Saadeddine, Hassen Mahfouf, Kamel Bouzid, Assia Bensalem, Taha Filali, Hikmat Abdel-Razeq, …

JCO global oncology, Vol.7(7), pp.811-819

01/12/2021

DOI: https://doi.org/10.1200/GO.20.00575

PMID: 34086481

Abstract

ORIGINAL REPORTS

Luminal, human epidermal growth factor receptor 2–negative breast cancer represents the most common subtype of breast malignancies. Neoadjuvant strategies of operable breast cancer are mostly based on chemotherapy, whereas it is not completely understood which patients might benefit from neoadjuvant hormone therapy (NAHT).

Files and links (1)

url

https://doi.org/10.1200/GO.20.00575View

Published (Version of record) Open

Metrics

1 Record Views

See more details

Details

Title: Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay—Results From the SAFIA Phase III Trial
Creators - without role: Khalid AlSaleh - King Saud University
Heba Al Zahwahry - Cairo University
Adda Bounedjar - University of Blida
Mohammed Oukkal - University of Algiers Benyoucef Benkhedda
Ahmed Saadeddine - King Abdulaziz Medical City
Hassen Mahfouf - Medical Oncology EPH, Rouiba, Algeria.
Kamel Bouzid - Marie Curie
Assia Bensalem - Centre Hospitalo-Universitaire Dr Benbadis Constantine
Taha Filali - Constantine 1 University
Hikmat Abdel-Razeq - King Hussein Cancer Center
Blaha Larbaoui - Emir Abdelkader University of Islamic Sciences
Alaa Kandil - Alexandria University
Omalkhair Abulkhair - Specialized Medical Center (SMC), Riyadh, Saudi Arabia.
Meteb Al Foheidi - King Abdulaziz Medical City
Hassan Errihani - Mohammed V University
Marwan Ghosn - Saint Joseph University
Nashwa Abdel-Aziz - King Saud University
Maria Arafah - King Saud University
Hamouda Boussen - Abderrahmane Mami Hospital
Farida Dabouz - University of Sharjah
Haleem Rasool - King Faisal Specialist Hospital & Research Centre
Mohun Bahadoor - University of Sharjah
Jihen Ayari - Military Hospital of Tunis
Sharif Kullab - King Saud University
Jean-Marc Nabholtz
Int Canc Res Grp
Publication Details: JCO global oncology, Vol.7(7), pp.811-819
Publisher: Wolters Kluwer Health
Identifiers: 9920733508331
Academic Unit: King Abdulaziz University; King Saud Bin Abdulaziz University for Health Sciences; King Saud University
Language: English
Resource Type: Journal article